Correction to: Nature Communications https://doi.org/10.1038/s41467-021-27407-0, published online 09 December 2021.
This Article contained an error in the Introduction and Discussion sections. The original version of the Article omitted a reference to a study that used a strategy to drive the expression of GSDMNT in rAAV by a Schwann-cell-specific promoter. The reference has now been included (new reference 18) and the Introduction and Discussion sections have been revised accordingly.
In the Introduction, the reference to this study has been added and the content of the second paragraph of the Introduction following the sentence “Moreover, rAAV has strong penetrability to solid tumors and has already been applied in tumor therapies15,16.” has been revised accordingly. In particular, the original sentence “However, GSDMNT is highly toxic to the cells due to its strong pore-forming activity, thus it is extremely difficult to biologically produce GSDMNT or package it on a large scale17.” now reads “However, GSDMNT is highly toxic to the cells17; its intracellular expression can lead to pyroptosis during AAV packaging and thus poses a challenge to delivery GSDMNT by AAV.” The following new sentence has been added that reads “While it is a good strategy to drive the expression of GSDMNT in rAAV by cell-specific promoter, as it has been successfully demonstrated with a Schwann-cell-specific promoter for Schwannoma cancer therapy18, some cell-specific promoters cannot completely avoid the leakage expression of GSDMNT during AAV packaging process, which may affect the titer of the virus.”
In the first paragraph of the Discussion, following the sentence that reads "However, owing to the extremely high cytotoxicity of GSDMNT during packaging, the conventional rAAV packaging approaches are impossible to achieve rAAV-GSDMNT with enough titer for clinical use.”, a new sentence has been added: “A Schwann-cell-specific promoter has been employed to control the expression of GSDMDNT during AAV packaging, which might be specifically used for schwannomas treatment18. However, different cell-specific promoters have different levels of leakage expression, which may affect the titer of the virus and increase the cost for the clinical gene therapy.”
Also in the first paragraph of the Discussion, following the original sentence “In this study, we developed two strategies and successfully packaged rAAV-GSDMNT, which can be potentially applied for antitumor therapy.” the following sentences have been added: “The compatibility between transcription factor and the underlying promoter is pivotal for gene expression. To maximize the divergence between the promoter and the potential transcription factors we employed a mammalian promoter and packaged the virus in insect cells, as the insect cell AAV packaging system is well established for large-scale AAV production by fermentation. After screening for several promoters, our data suggested that sf9 insect cells do not express the transcription factors to drive mCBA promoter activity (a promoter that can initiate gene expression in most mammalian cells). Thus, this strategy can produce high titers of rAAV-GSDMNT in sf9 cell that can be used for different types of tumor therapy.”
18. Ahmed, S. G., Abdelanabi, A., Doha, M. & Brenner, G. J. Schwannoma gene therapy by adeno-associated virus delivery of the pore-forming protein Gasdermin-D. Cancer Gene Ther 26, 259–267 https://doi.org/10.1038/s41417-018-0077-3 (2019).
The remaining reference numbers have also been updated in light of this addition. These errors have been corrected in the HTML and PDF versions of the Article.
About this article
Cite this article
Lu, Y., He, W., Huang, X. et al. Author Correction: Strategies to package recombinant Adeno-Associated Virus expressing the N-terminal gasdermin domain for tumor treatment. Nat Commun 13, 2932 (2022). https://doi.org/10.1038/s41467-022-29454-7